Researcher
Karin Haustermans
- Disciplines:Radiation therapy, Cancer diagnosis, Cancer therapy , Cancer epidemiology
Affiliations
- Laboratory of Experimental Radiotherapy (Division)
Responsible
From1 Jan 2012 → Today - Laboratory of Experimental Radiotherapy (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 36 results
- Implementation, optimisation and evaluation of proton therapy in esophageal cancerFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Proton versus Photon Therapy for Esophageal Cancer - a Trimodality StrategyFrom1 Jul 2021 → TodayFunding: H2020 - Health, demographic change and wellbeing
- The importance of the TNM Classification for Cancer Surveillance.From20 Oct 2020 → 30 Apr 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Accurate patient-individual prediction of proton therapy benefit in thoracic cancers using 3D dose maps and radiomicsFrom1 Oct 2020 → TodayFunding: FWO junior postdoctoral fellowship
- Characterization of the biological benefits of ultra-high dose rate FLASH proton therapy.From31 Aug 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Organ preserving strategies in rectal cancerFrom10 Aug 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimization of overall treatment time for whole gland stereotactic body radiotherapy with integrated focal boosting in prostate cancerFrom6 Aug 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Upgrade of the proton research beam line in the ParTICLe proton therapy center into a high precision proton irradiator.From1 May 2020 → TodayFunding: BOF - scientific equipment program
- Health effects of cArdiac fluoRoscopy and MOderN radIotherapy in paediatriCsFrom1 Jun 2019 → TodayFunding: H2020 - Euratom
- Extreme hypofractionated radiotherapy with a simultaneously integrated boost to the intraprostatic tumor to improve treatment outcome in prostate cancerFrom1 Jan 2019 → TodayFunding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 316 results
- ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies(2021)
Authors: Vincenzo Valentini, Francesco Cellini, Angela Riddell, Thomas B Brunner, Falk Roeder, Felice Giuliante, Sergio Alfieri, Riccardo Manfredi, Francesco Ardito, Claudio Fiorillo, et al.
Pages: 92 - 97Number of pages: 6 - Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME? Reply(2021)
Authors: Linda GW Kerkmeijer, Floris J Pos, Karin Haustermans, Uulke A van der Heide
Pages: 3086 - +Number of pages: 3 - Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial(2021)
Authors: Veerle H Groen, Nicolaas PA Zuithoff, Marcel van Schie, Evelyn M Monninkhof, Martina Kunze-Busch, Hans CJ de Boer, Jochem van der Voort van Zyp, Floris J Pos, Robert Jan Smeenk, Karin Haustermans, et al.
Pages: 98 - 104Number of pages: 7 - Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity(2021)
Authors: Nicola Rares Franco, Michela Carlotta Massi, Francesca Ieva, Andrea Manzoni, Anna Maria Paganoni, Paolo Zunino, Liv Veldeman, Piet Ost, Valerie Fonteyne, Christopher J Talbot, et al.
Pages: 241 - 248Number of pages: 8 - Ga-68-PSMA-11 PET, F-18-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability(2021)
Authors: Cédric Draulans, Floris Pos, Robert J Smeenk, Linda Kerkmeijer, Wouter V Vogel, James Nagarajah, Marcel Janssen, Cindy Mai, Stijn Heijmink, Marloes van der Leest, et al.
Pages: 202 - 211Number of pages: 10 - Parameters predicting [F-18]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer(2021)
Authors: Niloefar Ahmadi Bidakhvidi, Annouschka Laenen, Sander Jentjens, Christophe Deroose, Koenraad Van Laere, Liesbeth De Wever, Cindy Mai, Charlien Berghen, Gert De Meerleer, Karin Haustermans, et al.
Number of pages: 10 - A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy(2021)
Authors: Miha Orazem, Cédric Draulans, Mathieu Spaas, Eric Van Cutsem, Marina Debecker, Gert De Meerleer, Sabine Tejpar, Jeroen Dekervel, Karin Haustermans
Pages: 1121 - 1125Number of pages: 5 - Deep learning dose prediction for IMRT of esophageal cancer: The effect of data quality and quantity on model performance(2021)
Authors: Ana M Barragan-Montero, Melissa Thomas, Gilles Defraene, Steven Michiels, Karin Haustermans, John A Lee, Edmond Sterpin
Pages: 52 - 63Number of pages: 12 - Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer(2021)
Authors: Melissa Thomas, Hanna R Mortensen, Lone Hoffmann, Ditte S Moller, Esther GC Troost, Christina T Muijs, Maaike Berbee, Rebecca Butof, Owen Nicholas, Ganesh Radhakrishna, et al.
Pages: 102 - 112Number of pages: 11 - Dosimetric impact of intrafraction prostate rotation and accuracy of gating, multi-leaf collimator tracking and couch tracking to manage rotation: An end-to-end validation using volumetric film measurements(2021)
Authors: Robin De Roover, Rune Hansen, Wouter Crijns, Casper Gammelmark Muurholm, Kenneth Poels, Simon Skouboe, Karin Haustermans, Per Rugaard Poulsen, Tom Depuydt
Pages: 10 - 18Number of pages: 9